Endocrine Disruption Screening Market Growth & Opportunity 2028

Free Sample PDF Inquiry Before Buying
Biotechnology Endocrine Disruption Screening Market
report image

Endocrine Disruption Screening Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Assay Type (In-Vitro and In-Vivo), Application (Natural Materials and Synthetic Materials), Sources of Waste (Incineration and Landfill, Agricultural Runoff, Industrial and Municipal Effluents, Pulp Mill Effluents, Consumer Products, and Others), Method [Estrogen Receptor (ER) Transactivation, Androgen Receptor (AR) Transactivation, Androgen Receptor (AR) Modulation, Estrogen Receptor-Alpha (ER-Alpha) Binding, Estrogen Receptor-Beta (ER-Beta) Binding, Androgen Receptor (AR) Binding, Steroidogenesis, Aromatase Assay, and Others], and End User (Pharmaceutical and Biopharmaceutical Companies, Cosmetics and Household Product Companies, Food Industry, and Chemical Industry) and Geography

Publication Month: Nov 2021 | Report Code: TIPRE00025912 | No. of Pages: 226 | Category: Biotechnology | Status: Published

The endocrine disruption screening market is projected to reach US$ 153.30 million by 2028 from US$ 126.53 million in 2021; it is expected to grow at a CAGR of 2.8% during 2021 to 2028.

Many chemicals, both natural and man-made, have the potential to imitate or interfere with the endocrine system, which regulates the body's hormones. These chemicals, known as endocrine disruptors, have been linked to developmental, reproductive, brain, immunological, and other disorders. Endocrine disruptors can be present in a variety of ordinary items, such as some plastic bottles and containers, metal food can liners, detergents, flame retardants, food, toys, cosmetics, and pesticides. Pesticides, chemicals, and environmental toxins are screened using a two-tiered method for their potential effect on the oestrogen, androgen, and thyroid hormone systems by the endocrine disruptor screening.

Strategic Insights

Report Coverage - Endocrine Disruption Screening Market
Report CoverageDetails
Market Size Value inUS$ 126.53 million in 2021
Market Size Value byUS$ 153.30 million by 2028
Growth rateCAGR of 2.8% during 2021 to 2028
Forecast Period2021-2028
Base Year2021
No. of Pages226
No. of Tables138
No. of Charts & Figures89
Historical data availableYes
Segments coveredAssay Type, Application, Sources of Waste, Method, and End User, and Geography
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

The growth of the endocrine disruption screening market is attributed to the growing research in the biotechnology sector and the rising prevalence of endocrine disorders. However, the high cost of screening technology hampers the market growth.

Lucrative Regions in Endocrine Disruption Screening Market

Lucrative Regions in Endocrine Disruption Screening Market

Get more information on this report :


Market Insights
Growing Prevalence of Endocrine Disorders Drives Endocrine Disruption Screening Market

Acromegaly (overproduction of growth hormone), obesity, metabolic syndrome, impaired fasting glucose, impaired glucose tolerance, osteoporosis, osteopenia, mild-moderate hypovitaminosis D, erectile dysfunction, dyslipidemia, and thyroiditis are among the endocrine disorders that have a collective prevalence of at least 5% among the adults in the US. Of these conditions, Males have the highest incidence of erectile dysfunction, while females have the highest incidence of osteopenia/osteoporosis. Diabetes mellitus in children and pituitary adenoma are the least common conditions, affecting less than 1% of the US population. Adrenocortical carcinoma, pheochromocytoma, and pituitary adenomas are the conditions with the lowest incidence. Hyperparathyroidism and thyroid disorders are more common in women. Diabetes mellitus is most prevalent among ethnic minorities. Endocrine and metabolic diseases are among the most common modern human ailments, particularly in the US and other countries implementing ample nutrition and screening programs for high-risk individuals. Endocrine disorders such as hyperparathyroidism, primary and secondary hypogonadism, GH deficiency, and hypothyroidism can lead to other disorders, such as metabolic bone disease and diabetes mellitus. Thus, the growing prevalence and incidence of such conditions propel the demand for endocrine disruption screening products.

Assay Type-Based Insights

The endocrine disruption screening market, by assay type, is bifurcated into in-vitro and in-vivo. The in-vitro segment led the market in 2021, contributing to a market share of 64.45%, and is expected to retain its dominance during the forecast period to account for a market share of 65.73% of the overall revenue generated in 2028.

Endocrine Disruption Screening Market, by Assay Type – 2021 and 2028

Endocrine Disruption Screening Market, by Assay Type – 2021 and 2028

Get more information on this report :


Application-Based Insights

By application, the endocrine disruption screening market is bifurcated into natural materials and synthetic materials. In 2021, the natural materials segment held a larger share of the market. Moreover, the market for the same segment is expected to grow at a faster CAGR of 3.1% during 2021–2028.

Source of Waste-Based Insights

The endocrine disruption screening market, by source of waste, is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. In 2021, the incineration and landfill segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest CAGR of 3.5% during 2021–2028.

Method-Based Insights

The endocrine disruption screening market, by method, is segmented into estrogen receptor (ER) transactivation, androgen receptor (AR) transactivation, androgen receptor (AR) modulation, estrogen receptor-alpha (ER) binding, estrogen receptor beta (ER) binding, androgen receptor (AR) binding, steroidogenesis, aromatase assay, and others. In 2021, the estrogen receptor (ER) transactivation segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest CAGR of 3.7% from 2021 to 2028.

End-User-Based Insights

The endocrine disruption screening market, based on end use, is segmented into pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, food industry, and chemical industry. In 2021, the pharmaceutical and biopharmaceutical companies segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest CAGR of 3.3% during 2021–2028.

Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the endocrine disruption screening market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world.

The report segments endocrine disruption screening market as follows

Endocrine Disruption Screening Market – by Assay Type

  • In-Vitro
  • In-Vivo

Endocrine Disruption Screening Market – by Application

  • Natural Materials
  • Synthetic Materials

Endocrine Disruption Screening Market – by Sources of Waste

  • Incineration and Landfill
  • Agricultural Runoff
  • Industrial and Municipal Effluents
  • Pulp Mill Effluents
  • Consumer Products
  • Others

Endocrine Disruption Screening Market – by Method

  • Estrogen Receptor (ER) Transactivation
  • Androgen Receptor (AR) Transactivation
  • Androgen Receptor (AR) Modulation
  • Estrogen Receptor-Alpha (ER-alpha) Binding
  • Estrogen Receptor Beta (ER-beta) Binding
  • Androgen Receptor (AR) Binding
  • Steroidogenesis
  • Aromatase Assay
  • Others

Endocrine Disruption Screening Market – by End User

  • Pharmaceutical and Biopharmaceutical Companies
  • Chemical Industry
  • Food Industry
  • Cosmetics and Household Product Companies 

Endocrine Disruption Screening Market – by Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa
  • South and Central America
    • Brazil
    • Argentina
    • Rest of South and Central America

Company Profiles

  • CREATIVE BIOARRAY
  • XENOMETRIX AG
  • CHARLES RIVER LABORATORIES, INC.
  • EUROFINS SCIENTIFIC Ltd.
  • SMITHERS
  • SGS SA
  • JRF GLOBAL
  • MéRIEUX NUTRISCIENCES
  • ALPHA ANALYTICAL INC.

Frequently Asked Questions

What does endocrine disruption screening mean?
Many chemicals, both natural and man-made, can imitate or interfere with the endocrine system, which regulates the body's hormones. These chemicals, known as endocrine disruptors, have been related to developmental, reproductive, cognitive, immunological, and other issues. Many ordinary products include endocrine disruptors, such as some plastic bottles and containers, metal food can liners, detergents, flame retardants, food, toys, cosmetics, and pesticides. Some hormone-disrupting compounds take a long time to degrade in the environment. As a result of this trait, they can become dangerous over time. Pesticides, chemicals, and environmental toxins are screened using a two-tiered method for their potential effect on the estrogen, androgen, and thyroid hormone systems by the endocrine disruptor screening.
What are the driving factors for the endocrine disruption screening market across the globe?
The growth of the endocrine disruption screening market is mainly attributed to factors such as the increasing prevalence of endocrine disorders coupled with rising incidence of diabetes. However, the high cost of screening technology and devices is hindering the market growth. In July 2021, DDA platform, the division of Creative Bioarray, launched a wide range of genotoxicity testing services (non-GLP) into the service segment of in vitro toxicity services which is contributing to the growth of the target market. Such strategic steps are also projected to drive the market growth.
Which is the potential market for the endocrine disruption screening in terms of region??
The Asia Pacific region is expected to be the fastest-growing region among all other regions. The market is this region is expected to grow significantly in countries such as China, Japan, South Korea, and India. The growth of the market in this region is expected to grow at a faster pace owing to factors such as high prevalence of this hormonal changes, and the rise in healthcare awareness. Additionally, developing healthcare infrastructure and increasing investments are projected to drive the Asia Pacific endocrine disruption screening market during the forecast period.
What are future trends of endocrine disruption screening market?
Regulatory agencies throughout the world are grappling with the task of assessing the hazards and dangers to human and ecosystem health that may come from exposure to substances that disrupt the normal functioning of endocrine systems. The rapidly rising number of compounds in commerce, along with the dependence on conventional, expensive animal tests for hazard assessment – frequently with insufficient sensitivity to many critical processes of endocrine disruption – poses persistent problems for chemical management. As a result, there are only a few compounds for which there is enough evidence to determine whether there is endocrine toxicity, and hence only a few substances with full hazard categorization. To address this issue, regulatory assessment of endocrine disrupting chemicals (EDCs) is benefiting from a toxicology revolution focused on New Approach Methodologies (NAMs) to more rapidly identify, prioritize, and assess the potential risks from chemical exposure using novel, more efficient, and mechanistically driven methodologies, and tools.
What is the market CAGR value of endocrine disruption screening market during forecast period?
The global endocrine disruption screening market is expected to reach US$ 153.30 million by 2028 from US$ 126.53 million in 2021. The market is estimated to grow with a CAGR of 2.8% from 2021-2028.

The List of Companies - Endocrine Disruption Screening Market

  1. CREATIVE BIOARRAY
  2. XENOMETRIX AG
  3. CHARLES RIVER
  4. EUROFINS SCIENTIFIC
  5. SMITHERS
  6. SGS SA
  7. JRF GLOBAL
  8. MéRIEUX NUTRISCIENCES
  9. ALPHA ANALYTICAL
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Endocrine Disruption Screening Market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Endocrine Disruption Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00025912
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Download PDF Brochure

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550
Sample Download Download Free Sample

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount